Drug Approval | June 30, 2022
India’s first mRNA vaccine from Gennova gets DCGI approval
It is a two dose vaccine to be administered intramuscularly at 28 days apart
It is a two dose vaccine to be administered intramuscularly at 28 days apart
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
The three-year collaboration will focus on the development of new tools for computational chemistry modelling as well as new molecular representations to advance the next generation of molecular machine learning
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
